Nasal Atropine Sulfate

Abstract

Atropine sulfate, 50 or 75 microg 4 times daily, is effective in reducing rhinorrhea and postnasal drip within 2 weeks and may be an alternative therapy for the rhinorrhea component of rhinitis.

Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta‐Analysis

“…The characteristics of all included studies are summarized in Table I 18–29 . The average study subject was male (53.73% [43.31%, 63.99%]) and 31.7 years old (range: 6–75).…”

“…The characteristics of all included studies are summarized in Table I. [18][19][20][21][22][23][24][25][26][27][28][29] The average study subject was male (53.73% [43.31%, 63.99%]) and 31.7 years old (range: 6-75). Median follow-up was 4 weeks and ipratropium bromide was the most extensively trialed anticholinergic with 10 studies.…”

Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta‐Analysis

“…The characteristics of all included studies are summarized in Table I 18–29 . The average study subject was male (53.73% [43.31%, 63.99%]) and 31.7 years old (range: 6–75).…”

“…The characteristics of all included studies are summarized in Table I. [18][19][20][21][22][23][24][25][26][27][28][29] The average study subject was male (53.73% [43.31%, 63.99%]) and 31.7 years old (range: 6-75). Median follow-up was 4 weeks and ipratropium bromide was the most extensively trialed anticholinergic with 10 studies.…”

Atropine toxicity caused by erroneous intranasal administration in a pediatric patient: case report

“…6 In a previous study, nasal atropine sulfate was effective in reducing symptoms of rhinorrhea and postnasal drip with no systemic adverse events in adult patients with perennial allergic rhinitis. 12 Additionally, anticholinergic toxicity has been reported in a patient after instillation of multiple eye drops of atropine. 13 Another case reported a colicky infant with toxic symptoms after 12 hours of ingesting a mixture containing atropine.…”

Treatment of mucous hypersecretion

“…Atropine sulphate and ipratropium bromide are non‐selective muscarinic receptor antagonists that decrease severe rhinorrhea in perennial allergic rhinitis (PAR) but have no effect on other symptoms such as sneezing or congestion [17–19]. Intranasal pratropium (80 μg/puff four times daily) reduced watery rhinorrhea with no effect on blockage or sneezing in a double‐blind, placebo‐controlled, crossover trial of 20 chronic perennial rhinitis subjects [20].…”

Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta‐Analysis

“…The characteristics of all included studies are summarized in Table I 18–29 . The average study subject was male (53.73% [43.31%, 63.99%]) and 31.7 years old (range: 6–75).…”

“…The characteristics of all included studies are summarized in Table I. [18][19][20][21][22][23][24][25][26][27][28][29] The average study subject was male (53.73% [43.31%, 63.99%]) and 31.7 years old (range: 6-75). Median follow-up was 4 weeks and ipratropium bromide was the most extensively trialed anticholinergic with 10 studies.…”

Atropine toxicity caused by erroneous intranasal administration in a pediatric patient: case report

“…6 In a previous study, nasal atropine sulfate was effective in reducing symptoms of rhinorrhea and postnasal drip with no systemic adverse events in adult patients with perennial allergic rhinitis. 12 Additionally, anticholinergic toxicity has been reported in a patient after instillation of multiple eye drops of atropine. 13 Another case reported a colicky infant with toxic symptoms after 12 hours of ingesting a mixture containing atropine.…”

Treatment of mucous hypersecretion

“…Atropine sulphate and ipratropium bromide are non‐selective muscarinic receptor antagonists that decrease severe rhinorrhea in perennial allergic rhinitis (PAR) but have no effect on other symptoms such as sneezing or congestion [17–19]. Intranasal pratropium (80 μg/puff four times daily) reduced watery rhinorrhea with no effect on blockage or sneezing in a double‐blind, placebo‐controlled, crossover trial of 20 chronic perennial rhinitis subjects [20].…”

Intranasal Anticholinergics for Treatment of Chronic Rhinitis: Systematic Review and Meta‐Analysis

“…The characteristics of all included studies are summarized in Table I 18–29 . The average study subject was male (53.73% [43.31%, 63.99%]) and 31.7 years old (range: 6–75).…”

“…The characteristics of all included studies are summarized in Table I. [18][19][20][21][22][23][24][25][26][27][28][29] The average study subject was male (53.73% [43.31%, 63.99%]) and 31.7 years old (range: 6-75). Median follow-up was 4 weeks and ipratropium bromide was the most extensively trialed anticholinergic with 10 studies.…”

Atropine toxicity caused by erroneous intranasal administration in a pediatric patient: case report

“…6 In a previous study, nasal atropine sulfate was effective in reducing symptoms of rhinorrhea and postnasal drip with no systemic adverse events in adult patients with perennial allergic rhinitis. 12 Additionally, anticholinergic toxicity has been reported in a patient after instillation of multiple eye drops of atropine. 13 Another case reported a colicky infant with toxic symptoms after 12 hours of ingesting a mixture containing atropine.…”

Treatment of mucous hypersecretion

“…Atropine sulphate and ipratropium bromide are non‐selective muscarinic receptor antagonists that decrease severe rhinorrhea in perennial allergic rhinitis (PAR) but have no effect on other symptoms such as sneezing or congestion [17–19]. Intranasal pratropium (80 μg/puff four times daily) reduced watery rhinorrhea with no effect on blockage or sneezing in a double‐blind, placebo‐controlled, crossover trial of 20 chronic perennial rhinitis subjects [20].…”